Stock Market Reviews

Read and share opinions on SNGX (Soligenix, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• SNGX: DMC Reports No Safety Signals for Ongoing Phase 3 Trial in CTCL; Blinded Interim Efficacy Analysis in 1H26
  Nov 10, 2025
• Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results
  Nov 7, 2025
• Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma
  Oct 14, 2025
• Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
  Oct 7, 2025
• Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
  Sep 30, 2025
• SNGX: Public Offering Raises $7.5 Million; Expands European Medical Advisory Board
  Sep 30, 2025
• Soligenix Announces Closing of $7.5 Million Public Offering
  Sep 29, 2025
• Soligenix Announces Pricing of $7.5 Million Public Offering
  Sep 26, 2025
• Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor
  Sep 23, 2025
• Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses
  Sep 4, 2025
• Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference
  Sep 2, 2025
• Companies Like Soligenix (NASDAQ:SNGX) Could Be Quite Risky
  Aug 20, 2025
• SNGX: Dusquetide (SGX945) Granted Orphan Drug Designation for Behcet’s Disease
  Aug 20, 2025
• FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results
  Aug 18, 2025
• Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results
  Aug 14, 2025
• NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer
  Aug 8, 2025
• Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy
  Aug 7, 2025
• Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
  Aug 5, 2025
• SNGX: Encouraging Results from Phase 2a Study of SGX945 in Behcet’s Disease…
  Jul 31, 2025